What's New? | Canadian Urological Association

Area of Focused Competence (AFC)

Obtain Recognition of your expertise in Pediatric Urology through the Royal College of Physicians and Surgeons of Canada

The Royal College of Physicians and Surgeons of Canada (RCPSC) has recognized the Area of Focused Competence (AFC) in Pediatric Urology as a Royal College discipline, and has launched a Practice Eligibility Route for this area of focused competence (PER-AFC).

If you would like to have your competencies in Pediatric Urology recognized by the Royal College with an additional designation, we invite you to apply. Eligibility criteria are outlined in the application form, which can be requested at diplomas@royalcollege.ca.

This application process reviews your discipline specific scope of practice and collects feedback from a number of peers through multisource feedback. Your application will be reviewed by the AFC committee in Pediatric Urology to determine whether you meet the discipline’s requirements. The application fee is $1950 CDN and the annual fee for Diplomates is $250 CDN.

More information regarding the route and application process is available on the Royal College website: Practice Eligibility Route - AFC: The Royal College of Physicians and Surgeons of Canada

Andrew E MacNeily MD FRCSC
Chair, AFC Pediatric Urology Committee

Standard Synthetic Mid-urethral Sling

As an ongoing commitment to openness and transparency, Health Canada would like to notify you that a summary safety review (SSR) regarding standard synthetic mid-urethral slings and their long-term safety and effectiveness will be published (see attached document). The SSR is intended to provide Canadians with a sufficient understanding of the safety review conducted by Health Canada, specifically what was assessed, what was found and what action was taken.

Notification re. PLUVICTO™

Canadian Agency for Drugs and Technologies in Health (CADTH), Canadian Drug Expert Committee (CDEC) and the Institut national d'excellence en santé et services sociaux (INESSS) have recommended PLUVICTO™ (lutetium (¹⁷⁷Lu) vipivotide tetraxetan injection) for public reimbursement for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have received at least one androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and meet certain conditions.

PLUVICTO™ was approved by Health Canada in August 2022 as a targeted radioligand therapy for the treatment of PSMA-positive mCRPC in Canada¹.

For additional information:

CADTH | CADTH INESSS: WWW-Anglais

Listing of CUA Clinical Tools

CUA-developed clinical tools are all available just one click away on:

Integration of TICE and VERITY-BCG(TM)

TO: Physicians Prescribing Treatment for Non-muscle Invasive Bladder Cancer (NMIBC)

Until 2021, TICE BCG was the only strain available in Canada.
A second strain of BCG recently received conditional approval by Health Canada in 2021 and is available in the Canadian market: VERITY-BCGTM.
The past shortage of BCG is therefore resolved.

The Medical Advisory Board of Bladder Cancer Canada, with endorsement by the Canadian Urological Association (2021), has reviewed and support the following suggestions. Click "READ MORE" for full details.

Lupron Depot are Now Back in Stock

AbbVie is pleased to inform you that all formulations of LUPRON DEPOT are now available. More importantly, the inventory shortage which affected the availability of LUPRON DEPOT has now been completely resolved. We do not foresee any future disruptions.

An update on transvaginal mesh for CUA Members

Blayne Welk, Duane Hickling, Greg Bailly, Stephen Steele, Richard Baverstock, Jacques Corcos, Kevin Carlson

2019